Camlin Fine Sciences Ltd
Camlin Fine Sciences Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
3 of 3 strong
Not discussed on this call: capex, order book.
The short version
Vanillin demand expected to pick up with an estimated 3,000 to 4,000 tons for the year, though production may be limited due to ongoing campaigns (Page 17). EBITDA expected to improve by at least 6% if raw material and margin pressures normalize (Page 18).
From Camlin Fine Sciences Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Vanillin demand expected to pick up with an estimated 3,000 to 4,000 tons for the year, though production may be limited due to ongoing campaigns (Page 17).
- Peak vanillin plant utilization aimed at 5,000 tons per year with up to 3 campaigns annually (Page 17).
- Revenue guidance targets INR2,200 to INR2,300 crores for the full year with EBITDA margins of 10-11% (Page 6).
- Blends growing at a 20% CAGR, showing strong growth momentum (Page 13).
- Expected average EBITDA run rate around INR70 crores for coming quarters, with Q3 and Q4 potentially higher (Page 18).
- Capacity utilization improvements across segments should lead to better EBITDA and revenue growth (Pages 8, 9, 18).
Profitability & Margins
See what Camlin Fine Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is working on alternatives for the diphenol plant, considering new phenolic compounds as potential products. A decision regarding the plant's future use or restart is expected by the third quarter. (Page 6)
- There is a focus on scaling up vanillin production campaigns, with plans to ideally run up to 3 campaigns a year and reach production capacity of around 5,000 tons, indicating potential capacity investments or utilization of existing capacity. (Page 17)
- Management is evaluating ways to "sweat" the existing Performance Chemicals plant assets to achieve better margins and returns; options are being finalized in the coming months. (Page 15)
- Capital raising efforts are underway to support growth and working capital needs, with plans to secure INR100-150 crores of credit lines in the next 1-1.5 months. (Page 16)
- No immediate large-scale capex is detailed, but strategic decisions around plant utilization and product portfolio are active. (Pages 6, 15, 16)
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Camlin Fine Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Camlin Fine Sciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹425 Cr, net profit ₹86 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Camlin Fine's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Solar Industries India Ltd (Q1 FY27)
EBITDA margin improvement potential in explosive business to reach mid-teens (18-19% global benchmarks), with combined Solar-BME margins currently at 13-14%…
- Sudarshan Chemical Industries Ltd (Q1 FY27)
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
- Indo Borax & Chemicals Ltd (Q1 FY27)
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
- SRF Ltd (Q1 FY27)
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…
Frequently Asked Questions
What were Camlin Fine Sciences Ltd Q1 FY27 results?
Vanillin demand expected to pick up with an estimated 3,000 to 4,000 tons for the year, though production may be limited due to ongoing campaigns (Page 17). EBITDA expected to improve by at least 6% if raw material and margin pressures normalize (Page 18).
What is Camlin Fine Sciences Ltd share price analysis?
Camlin Fine Sciences Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of N/A with a market cap of ₹1,993 Cr. Investors should review the full earnings analysis for detailed insights.
Is Camlin Fine Sciences Ltd planning capital expenditure?
The company is working on alternatives for the diphenol plant, considering new phenolic compounds as potential products.
Keep Camlin Fine Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.